{"altmetric_id":1260487,"counts":{"readers":{"mendeley":17,"citeulike":0,"connotea":0},"blogs":{"unique_users_count":1,"unique_users":[55658],"posts_count":1},"total":{"posts_count":2},"twitter":{"unique_users_count":1,"unique_users":["joaprimo"],"posts_count":1}},"selected_quotes":["MK-7009 (Vaniprevir) in Patients with Genotype 1 HCV Infection who have Failed Previous PegIFN and RBV Treatment."],"citation":{"abstract":"MK-7009 (vaniprevir) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3\/4A protease. This report presents the primary analysis results (safety and sustained viral response) of a phase 2b study of MK-7009 given in combination with peginterferon (PegIFN) alfa2a 180 \u03bcg weekly and ribavirin (RBV) 1000-1200 mg\/day, for 24-48 weeks to non-cirrhotic patients who have failed previous PegIFN and RBV treatment.","abstract_source":"pubmed","altmetric_jid":"4f6fa4f53cf058f610002ddb","authors":["Lawitz, Eric","Rodriguez-Torres, Maribel","Stoehr, Albrecht","Gane, Edward J.","Serfaty, Lawrence","Bhanja, Sanhita","Barnard, Richard J.","An, Di","Gress, Jacqueline","Hwang, Peggy","Mobashery, Niloufar","Eric Lawitz","Maribel Rodriguez-Torres","Albrecht Stoehr","Edward J. Gane","Lawrence Serfaty","Sanhita Bhanja","Richard J. Barnard","Di An","Jacqueline Gress","Peggy Hwang","Niloufar Mobashery"],"doi":"10.1016\/j.jhep.2013.02.008","first_seen_on":"2013-02-24T13:28:57+00:00","issns":["0168-8278","01688278"],"journal":"Journal of Hepatology","last_mentioned_on":1388364900,"links":["http:\/\/www.sciencedirect.com\/science\/article\/pii\/S016882781300130X","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23439259"],"pdf_url":"http:\/\/www.journal-of-hepatology.eu\/article\/S0168-8278(13)00130-X\/pdf","pmid":"23439259","pubdate":"2013-02-22T00:00:00+00:00","publisher":"Elsevier","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["gastroenterology"],"title":"A Phase 2b Study of Mk-7009 (Vaniprevir) in Patients with Genotype 1 Hcv Infection who have Failed Previous Pegylated Interferon and Ribavirin Treatment","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/phase-2b-study-mk7009-vaniprevir-patients-genotype-1-hcv-infection-failed-previous-pegylated-interfe"},"altmetric_score":{"score":7.748,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7.748},"context_for_score":{"all":{"total_number_of_other_articles":8040840,"mean":6.830780832196,"rank":1078479,"this_scored_higher_than_pct":86,"this_scored_higher_than":6962873,"rank_type":"exact","sample_size":8040840,"percentile":86},"similar_age_3m":{"total_number_of_other_articles":116916,"mean":6.5645482444511,"rank":16922,"this_scored_higher_than_pct":85,"this_scored_higher_than":99993,"rank_type":"exact","sample_size":116916,"percentile":85},"this_journal":{"total_number_of_other_articles":2193,"mean":8.7189461678832,"rank":487,"this_scored_higher_than_pct":77,"this_scored_higher_than":1705,"rank_type":"exact","sample_size":2193,"percentile":77},"similar_age_this_journal_3m":{"total_number_of_other_articles":37,"mean":9.4943888888889,"rank":10,"this_scored_higher_than_pct":72,"this_scored_higher_than":27,"rank_type":"exact","sample_size":37,"percentile":72}}},"demographics":{"poster_types":{"practitioner":1},"users":{"twitter":{"cohorts":{"Practitioners (doctors, other healthcare professionals)":1}},"mendeley":{"by_status":{"Professor > Associate Professor":2,"Researcher":4,"Student  > Ph. D. Student":2,"Student  > Postgraduate":1,"Student  > Master":3,"Other":2,"Lecturer > Senior Lecturer":1,"Professor":2},"by_discipline":{"Medicine and Dentistry":12,"Immunology and Microbiology":1,"Agricultural and Biological Sciences":3,"Biochemistry, Genetics and Molecular Biology":1}}},"geo":{"mendeley":{"JP":1,"BR":1}}},"posts":{"blogs":[{"title":"Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review","url":"http:\/\/hepatitiscresearchandnewsupdates.blogspot.com\/2013\/12\/hepatitis-c-virus-protease-inhibitor.html","citation_ids":[1178609,21710141,627468,21710142,3169760,221247,548402,16554562,531574,174813,174814,269862,21710145,3182562,21710147,21710149,21710152,21710154,21710157,407953,407950,537809,21710162,3199837,21710164,21710167,21710169,21710171,21710175,1204505,1158616,21710178,2839849,210637,399526,565204,1714392,1364739,21710186,1689885,21710190,928672,1260487,21710195,755305,21710200,21710202,21710203,631524,21710211,21710214,1654308,21710217,21710218,1011791,2344943,11854801,21710224,21710226,20487732,21710232,21710236,21710239,21710242,16664761,21649967,21710246,21710249,21710250,1059512,392517,21710252,21710253,1744127,21710254,2345358,441971,387545,3169910,889342,21710256],"posted_on":"2013-12-30T00:55:00+00:00","summary":"World J Gastroenterol 2013 December 21; 19(47): 8940-8948  Copyright \u00a92013 Baishideng Publishing Group Co., Limited. All rights reserved.  Shuang Wu, Tatsuo Kanda, Shingo Nakamoto, Fumio Imazeki and Osamu Yokosuka.  Shuang Wu, Tatsuo Kanda, Shingo Nakamoto","author":{"name":"HCV Research and News","url":"http:\/\/hepatitiscresearchandnewsupdates.blogspot.com\/","description":""}}],"twitter":[{"url":"http:\/\/twitter.com\/joaprimo\/statuses\/305670626025287681","license":"datasift","citation_ids":[1260487],"posted_on":"2013-02-24T13:28:50+00:00","author":{"name":"Joaqu\u00edn Primo","image":"https:\/\/pbs.twimg.com\/profile_images\/840124959968051201\/xMlS50zI_normal.jpg","description":"JUBILADO. Exjefe de Secci\u00f3n de Medicina Digestiva, Hospital de Sagunto","id_on_source":"joaprimo","tweeter_id":"558853052","geo":{"lt":null,"ln":null},"followers":324},"tweet_id":"305670626025287681"}]}}